Tredje AP fonden decreased its position in Boston Scientific Co. (NYSE:BSX) by 13.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 84,857 shares of the medical equipment provider’s stock after selling 13,294 shares during the quarter. Tredje AP fonden’s holdings in Boston Scientific were worth $3,837,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Jennison Associates LLC increased its position in shares of Boston Scientific by 526.5% in the fourth quarter. Jennison Associates LLC now owns 11,358,459 shares of the medical equipment provider’s stock valued at $513,630,000 after acquiring an additional 9,545,336 shares during the last quarter. First Trust Advisors LP lifted its position in Boston Scientific by 431.4% in the 3rd quarter. First Trust Advisors LP now owns 1,806,774 shares of the medical equipment provider’s stock valued at $73,518,000 after acquiring an additional 1,466,762 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in Boston Scientific by 1,787.5% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,457,261 shares of the medical equipment provider’s stock valued at $65,897,000 after acquiring an additional 1,380,055 shares in the last quarter. State Street Corp lifted its position in Boston Scientific by 1.8% in the 4th quarter. State Street Corp now owns 60,256,156 shares of the medical equipment provider’s stock valued at $2,724,783,000 after acquiring an additional 1,080,641 shares in the last quarter. Finally, Strs Ohio lifted its position in Boston Scientific by 117.4% in the 4th quarter. Strs Ohio now owns 1,455,691 shares of the medical equipment provider’s stock valued at $65,826,000 after acquiring an additional 785,957 shares in the last quarter. 90.13% of the stock is owned by institutional investors and hedge funds.
Boston Scientific stock traded down $1.25 during midday trading on Tuesday, reaching $39.83. The company’s stock had a trading volume of 528,323 shares, compared to its average volume of 8,120,774. The firm has a market capitalization of $57.22 billion, a PE ratio of 11.98, a P/E/G ratio of 2.40 and a beta of 0.87. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.77 and a current ratio of 1.14. Boston Scientific Co. has a fifty-two week low of $34.35 and a fifty-two week high of $46.62. The stock’s 50 day simple moving average is $43.34 and its 200 day simple moving average is $42.47.
Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.02. The business had revenue of $2.91 billion during the quarter, compared to the consensus estimate of $2.92 billion. Boston Scientific had a return on equity of 23.62% and a net margin of 43.78%. The business’s revenue was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.39 EPS. Equities analysts predict that Boston Scientific Co. will post 1.77 earnings per share for the current year.
In other Boston Scientific news, SVP Wendy Carruthers sold 24,220 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $45.03, for a total transaction of $1,090,626.60. Following the completion of the sale, the senior vice president now directly owns 168,848 shares in the company, valued at $7,603,225.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David A. Pierce sold 5,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $43.33, for a total value of $216,650.00. Following the sale, the executive vice president now owns 29,201 shares of the company’s stock, valued at $1,265,279.33. The disclosure for this sale can be found here. Insiders have sold a total of 205,288 shares of company stock valued at $9,117,768 in the last quarter. Company insiders own 0.66% of the company’s stock.
Several brokerages recently weighed in on BSX. Cowen reaffirmed a “buy” rating and issued a $52.00 price target on shares of Boston Scientific in a research report on Wednesday, January 15th. Canaccord Genuity restated a “buy” rating and set a $58.00 price target on shares of Boston Scientific in a research note on Thursday, February 6th. Needham & Company LLC lowered shares of Boston Scientific from a “strong-buy” rating to a “buy” rating and set a $53.00 price target for the company. in a research note on Thursday, December 19th. ValuEngine lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday, November 19th. Finally, JPMorgan Chase & Co. raised their price target on shares of Boston Scientific from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. Two investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Boston Scientific presently has a consensus rating of “Buy” and an average price target of $49.48.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Recommended Story: What is the Coverage Ratio?
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.